AMAG Pharmaceuticals Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stocks set for lower open as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Goldman Sachs to acquire real estate company LCN for up to $410M
AMAG Pharma (AMAG) Misses Q3 EPS by 16c; Boosts FY15 Outlook
November 3, 2015 7:33 AM ESTAMAG Pharma (NASDAQ: AMAG) reported Q3 EPS of $1.02, $0.16 worse than the analyst estimate of $1.18. Revenue for the quarter came in at $103.5 million versus the consensus estimate of $113.88 million.
AMAG Pharma sees FY2015 revenue of $425-450 million, versus prior guidance of $395-430 million and the... More
